Stay updated with breaking news from Nasdaq Clsd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) has been given an average recommendation of “Buy” by the four ratings firms that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have covered the stock in the […]
StockNews.com began coverage on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a research report report published on Friday. The brokerage issued a hold rating on the stock. CLSD has been the subject of several other reports. Needham & Company LLC reissued a buy rating and issued a $4.00 price objective on shares of […]
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) posted its earnings results on Monday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01, Yahoo Finance reports. The firm had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.22 million. Clearside Biomedical […]
ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...
Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 350,500 shares, a drop of 8.5% from the September 15th total of 382,900 shares. Approximately 0.7% of the shares of the company are […]